Epistem Signs $4M Biomarker Deal with Sanofi-Aventis; Preps PoC Platform for Companion Diagnostics

Epistem is currently beta-testing a point-of care molecular diagnostic platform called Genedrive that will be able to deliver test results in under 30 minutes. The company sees the platform as a natural translation path for its biomarker discovery business.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.